A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...